Deferred Tax Assets, Valuation Allowance of Theravance Biopharma, Inc. from 31 Dec 2013 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Theravance Biopharma, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2013 to 31 Dec 2024.
  • Theravance Biopharma, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $435,543,000, a 1.3% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Theravance Biopharma, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $435,543,000 +$5,693,000 +1.3% 31 Dec 2024 10-K 07 Mar 2025 2024 FY
Q4 2023 $429,850,000 +$7,525,000 +1.8% 31 Dec 2023 10-K 07 Mar 2025 2024 FY
Q4 2022 $422,325,000 -$55,543,000 -12% 31 Dec 2022 10-K 01 Mar 2024 2023 FY
Q4 2021 $477,868,000 +$15,157,000 +3.3% 31 Dec 2021 10-K 01 Mar 2023 2022 FY
Q4 2020 $462,711,000 +$58,875,000 +15% 31 Dec 2020 10-K 28 Feb 2022 2021 FY
Q4 2019 $403,836,000 +$36,088,000 +9.8% 31 Dec 2019 10-K 26 Feb 2021 2020 FY
Q4 2018 $367,748,000 +$325,135,000 +763% 31 Dec 2018 10-K 27 Feb 2020 2019 FY
Q4 2017 $42,613,000 +$14,148,000 +50% 31 Dec 2017 10-K 28 Feb 2019 2018 FY
Q4 2016 $28,465,000 +$1,643,000 +6.1% 31 Dec 2016 10-K 28 Feb 2018 2017 FY
Q4 2015 $26,822,000 +$8,035,000 +43% 31 Dec 2015 10-K 01 Mar 2017 2016 FY
Q4 2014 $18,787,000 -$163,902,000 -90% 31 Dec 2014 10-K 11 Mar 2016 2015 FY
Q2 2014 $13,000,000 02 Jun 2014 10-K 13 Mar 2015 2014 FY
Q4 2013 $182,689,000 31 Dec 2013 10-K 13 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.